The American Society of Hematology (ASH) held its annual meeting and exposition December 9-12, 2023, in San Diego, California, where experts from around the world convened to explore the latest developments in hematologic research. Below is a selection from the Journal of Clinical Pathways’ online news coverage of the conference that provides a look at the discoveries, emerging therapies, and breakthroughs presented during the event.

VIDEO: The Impact of Racial and Socioeconomic Disparities in Patients With Chronic Lymphocytic Leukemia

In this video interview, Ira Zackon, MD, New York Oncology Hematology, speaks with the Journal of Clinical Pathways about the abstract he presented at the 2023 ASH Annual Meeting & Exposition titled “Racial and Socioeconomic Disparities Among Patients With Chronic Lymphocytic Leukemia (CLL) Treat­ed in the US Community Oncology Setting.”

Real-World Clinical Effectiveness of Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-Cell lymphoma.

Incidence and Survival Outcomes of Diffuse Large B-Cell Lymphoma in Adolescents and Young Adults

To determine the influence of race on the occurrence and survival outcomes of diffuse large B-cell lymphoma (DLBCL) among adolescents and young adults, Mustafa Wasifuddin, MD, Brookdale University Hospital and Medical Center, Brooklyn, New York, and colleagues gathered data from the Surveillance, Epidemiology, and End Results database to quantify changes in the incidence of DLBCL and identify the factors that affect survival rates among different racial and ethnic groups.

Efficacy and Safety of Real-World Treatments of Teclistamab for Patients With Pretreated Relapsed/Refractory Multiple Myeloma

Danai Dima, MD, and colleagues examined the real-world safety and efficacy of teclistamab for treating patients with relapsed/refractory multiple myeloma who have had at least four prior lines of therapy.

Key Factors Influencing Survival Rates in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.

For more highlights, speaker interviews, and in-depth coverage of the conference, visit the ASH Annual Meeting and Exposition newsroom.